Published in final edited form as:

Tetrahedron Lett. 2006 November 20; 47(47): 8267–8270.

Synthetic Studies Toward Bryostatin 1: Preparation of a C₁-C₁₆ Fragment by Pyran Annulation

Gary E. Keck^{*}, Dennie S. Welch[†], and Yam B. Poudel

Department of Chemistry, University of Utah, 315 South 1400 East, RM 2020, Salt Lake City, Utah 84112-0850, USA

Abstract

An expeditious assembly of a C₁-C₁₆ subunit of bryostatin 1 is described. A pyran annulation reaction was utilized to form the B-ring by reaction of a hydroxy-allylsilane with a fully elaborated A-ring subunit. This annulation process proceeded with complete diastereoselectivity and in excellent isolated yield despite the presence of potentially sensitive functionality in the A-ring segment.

Keywords

Bryostatin; Chelation; A llylation; Stannane

Bryostatin 1, isolated by Petit and co-workers from a marine bryozoan in 1982,^{1,2} is of great interest as a potential chemotherapeutic agent for cancer, with some 80 clinical trials completed or ongoing.³ Although bryostatin 1 has shown limited utility as a single agent, remarkable synergies with established chemotherapy regimes have been documented.⁴ Recent studies have also revealed a role for this agent in memory and as a potential therapeutic for Alzheimer's disease.⁵ Although the exact mode of action of bryostatin with respect to these biological effects remains unknown, its exceptionally high affinity for protein kinase C (PKC) isozymes is well-established.⁶ Structurally, this 20-membered macrolactone with a polyacetate backbone that houses three pyran ring continues to be a daunting challenge as only three completed total syntheses⁷⁻⁹ of bryostatin have been disclosed despite the many ongoing investigations that are directed toward the total synthesis of this impressive target.¹⁰

An approach to the synthesis of bryostatin 1 is indicated in Scheme 1. Here, application of our pyranannulation methodology,¹¹ which has found success in our bryostatin analogue program,¹² was envisioned to unite a C-ring β -hydroxy allyls ilane such as **3** with an A-ring subunit **2**, with concurrent formation of the B-ring (Scheme 1). However, the presence of the lactol methyl ether in **2**, and its disposition β to the aldehyde carbonyl, was regarded as a potentially disastrous liability due to the strong Lewis acidic conditions (TMSOTf) required to promote the annulation process. We expected that the A-ring aldehyde **2** would be available from acyclic precursor **4**, which can be seen to possess an *anti*, *anti* relationship of the C₃-C₅-C₇ stereotriad. Thus the C₅ stereocenter could potentially be employed to control the stereoselective introduction of the C₃ and the C₇ stereocenters in sequential chelation-controlled additions at both ends of a β -alkoxy dialdehyde such as **6**.^{13, 14} The formation of the initial C₅ stereocenter with high stereoselectivity would thus be imperative. It was hoped that our catalytic asymmetric allylation (CAA)¹⁵ reaction would satisfy this requirement. The *p*-methoxybenzyl group was regarded as an ideal protecting group for the C₅ hydroxyl based upon its compatibility with chelating Lewis acids.

^{*}Corresponding author. Tel.: +1 801 581 7055; email: keck@chem.utah.edu

[†]Present address: Dept. of Chemistry, Harvard University, Cambridge, MA 02139, USA

The synthesis of the requisite C₁-C₇ aldehyde fragment along these lines has been recently disclosed and is summarized in Scheme 2.¹⁶ This route affords **12** in 57% yield over the eight step sequence.

In the most critical operation required to prepare the A-ring intermediate **2**, allylstannane **7** was to be employed to introduce the *gem*-dimethyl group in a stereoselective addition reaction with an aldehyde such as **6**. We have found the preparation of such allylstannanes incorporating the tetrasubstituted olefin structural motif to be a challenging proposition. Ultimately, we devised a route to such intermediates via a sequence utilizing the vinylogous alkylation of ester enolates. (Scheme 3). Thus, alkylation of the extended lithium enolate of commercially available ethyl 2,2-dimethylacrylate with iodide **14** derived from iodo-ethanol proceeded in 79% yield.¹⁷ Migration of the olefin to give the thermodynamically favored α,β -unsaturated ester **16** was effected by exposure to *t*-BuOK in THF in 93% yield. Here it was found that rigorous exclusion of oxygen during the isomerization was necessary to prevent autoxidation of the potassium enolate.¹⁸ Full-reduction of the ester proceeded uneventfully to give the allylic alcohol **17**.

This set the stage for introduction of the stannyl moiety, which unexpectedly proved to be rather difficult. Our initial intention was to convert the alcohol to the corresponding bromide or chloride and effect a displacement reaction with tributyltinlithium.¹⁹ However, attempted conversion of the alcohol to the corresponding chloride or bromide yielded compounds that proved unstable with respect to isolation and purification. It was critical that pure materials be obtainable here to preclude extensive purification of the desired allylstannane. It was thus necessary to convert the hydroxyl functionality to a suitable leaving group followed by direct exposure, without workup, to the tin nucleophile. This in turn required that the reaction used to activate the hydroxyl group be free of byproducts which could interfere with the use of tributyltinlithium. The most efficient manner devised to accomplish this proceeded via *in situ* formation of the mesylate at -78°C (reaction of the alcohol with 1 equiv of *n*-BuLi followed by the addition of mesyl chloride) followed by addition of tributyltinlithium and slow warming of the mixture to room temperature.¹⁸ This afforded allylstannane **7** in 50% overall yield for the sequence (from ester **13**).

Consistent with our previous observations,¹⁶ the nucleophilic addition of stannane **7** to aldehyde **12** required the use of a strongly activating Lewis acid with the ability to chelate, as neither MgBr₂·OEt₂ nor Ti(Cl)₂(*Oi*-Pr)₂ provided sufficient activation to promote this reaction (Scheme 4). In the event, precomplexation of the aldehyde **12** with excess Me₂AlCl in toluene at -78 °C followed by the addition of stannane **7** afforded the coupled product **18** in 86% yield and as a single diastereomer as judged by ¹H and ¹³C NMR spectroscopy.²⁰

Conversion of this acyclic material to the A-ring of bryostatin **1** first required acetylation of the C₇ hydroxyl group, which proceeded uneventfully under standard conditions to give acetate **19** in 94% yield (Scheme 5). Subsequent oxidative PMB removal was realized in 94% yield under buffered DDQ conditions. Ozonolysis with reductive work-up proceeded in 91% yield to give lactol **20** as the sole product; none of the open-chain keto-alcohol isomer was detected by ¹H NMR of the crude reaction product. The stereochemistry about the A-ring was established unambiguously at this stage by an NOE experiment which revealed interactions between the C₅, C₇, and lactol OH protons, thereby confirming the suspected stereochemical outcome of the key fragment coupling reaction. Deprotection of the TBS ether with simultaneous formation of the methyl ketal was carried out in a single operation by treatment with acidic methanol to give the corresponding primary alcohol. Subsequent Parikh-Doering oxidation then afforded the desired aldehyde A-ring subunit **2** in 88% yield.

In the critical event, subjection of an ether solution of aldehyde **2** and the known β -hydroxy allylsilane **21**¹¹ to the action of TMSOTf at -78 °C yielded the AB bicycle **22** in 85% yield and as a single diastereomer, thus confirming the viability of **2** as a suitable substrate for the pyran annulation. The expected stereochemistry of the newly formed pyran was corroborated by diagnostic NOE transfers from the C₁₁ proton to the C₁₅ and C₉ methoxy protons. Our concerns regarding the potential Lewis acid lability of the mixed acetal β to the aldehyde during the pyran annulation were not totally unfounded, however. It was noted that aldehyde **2** was quite acid sensitive in that it proved unstable in CDCl₃ as NMR solvent unless the CDCl₃ was pretreated with K₂CO₃. Moreover, it was found that monitoring of the pyran annulation reaction itself by TLC gave misleading results using aliquots spotted directly from the reaction mixture, as products other than **22** were observed as the major materials. Only the disappearance of starting materials could be reliably monitored in this way. After completion of the reaction and quenching at low temperature, however, **2** is observed as essentially the only product. It should be noted that the pyran annulation reaction was best quenched cold (at -78 °C) initially by addition of Hünigs base followed by the addition of aqueous NaHCO₃ solution.

The success of the pyran annulation to form the B-ring with the model allylsilane suggests that A-ring aldehyde **2** could be joined with a more complex C-ring β -hydroxy allylsilane, as proposed in our retrosynthetic analysis (Scheme 1). It worth noting that the AB bicyclic material **22** was accessed in 26% overall yield, over a 17 step sequence that began with commercially available 1,3-propanedio l. This represents, to the best of our knowledge, the most expedient route to an AB bicyclic system of bryostatin 1 reported to date. In this regard, it should be noted that both Evans and Yamamura have documented that the exocyclic enoate at C₁₃ in bryostatin 1 can be introduced in advanced intermediates (with the entire macrocyclic skeleton in place) using the BINOL based phosphonate reagent developed by Fuji.²¹ Thus introduction of the unsaturated ester is anticipated to require two additional steps of oxidative olefin cleavage and Emmons reaction. Efforts to extend the strategy and methodology described herein to the total synthesis of bryostatin 1 and analogues are in progress.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support from the National Institutes of Health (through GM-28961) is gratefully acknowledged. Mr. Robert Giles is acknowledged for helpful discussions regarding the synthesis and application of allylstannane 7.

References

1. Pettit GR;CL, Douobek DL, Herald DL. J. Am. Chem. Soc 1982;104:6846–6848.
2. For comprehensive reviews on the bryostatin family, see(a) Hale KJ, Hummersome MG, Manaviazar S, Frigerio M. Nat. Prod. Rep 2002;19:413–453. [PubMed: 12195811] (b) Mutter R, Wills M. Bioorg. Med. Chem 2000;8:1841–1860. [PubMed: 11003129]
3. Newmann DJ, Cragg GM. J. Nat. Prod 2004;67:1216–1238. [PubMed: 15332835]
4. Schwartz GK, Shah MA. J. Clin. Oncol. 2005;23:9408–9421. [PubMed: 16361640]
5. (a) Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, VanLeuven F, Alkon DL. Proc. Natl. Acad. Sci. U. S. A 2004;101:11141–11146. [PubMed: 15263077] (b) Akron DL, Epstein H, Kuzirian A, Bennett MC, Nelson TJ. Proc. Natl. Acad. Sci. U. S. A 2005;102:16432–16437. [PubMed: 16258064] (c) Sun MK, Alkon DL. Eur. J. Pharmacol. 2005;512:45–51.
6. (a) Dell'Aquila ML, Harold CL, Kamano Y, Pettit GR, Blumberg PM. Cancer Res 1988;48:3702–3708. [PubMed: 3132318] (b) Gschwendt M. Eur. J. Biochem 1999;259:555–564. [PubMed: 10533333]

- 10092837] (c) Ron D, Kazanietz MG. *FASEB J* 1999;13:1658–1676. [PubMed: 10506570] (d) Ma D. *Curr. Med. Chem* 2001;8:191–202. [PubMed: 11172674] (e) Bridges AJ. *Chem. Rev* 2001;101:2451–2571. (f) Ravandi F, Talpaz M, Estro v Z. *Clin. Cancer Res.* 2003;9;:535–550. [PubMed: 12576416] (g) Koivunen J, Aaltonen V, Peltonen J. *Cancer Lett* 2006;235:1–10.
7. Kageyama M, Tamura T, Nantz MH, Roberts JC, Somfai P, Whritenour DC, Masamune S. *J. Am. Chem. Soc* 1990;112:7407–7408.
8. Evans DA, Carter PH, Carreira EM, Charette AB, Prunet JA, Lautens M. *J. Am. Chem. Soc* 1999;121:7540–7552.
9. Ohmori K, Ogawa Y, Obitsu T, Ishikawa Y, Nishiyama S, Yamamura S. *Angew. Chem. Int. Ed* 2000;39:2290–2294.
10. For recent synthetic work in this area, see (a) Voight EA, Seradj H, Roethle PA, Burke SD. *Org. Lett* 2004;6:4045–4048. [PubMed: 15496095] (b) Voight EA, Roethle PA, Burke SD. *Org. Lett* 2004;6:4534–4537. (c) Hale KJ, Frigerio M, Manaviazar S, Hummersome MG, Fillingham IJ, Barsuko v IG, Damblon CF, Gerscher A, Roberts GCK. *Org. Lett* 2003;5:503–505. [PubMed: 12583754] (d) Hale KJ, Frigerio M, Hummersome MG, Manaviazar S. *Org. Lett* 2003;5:499–502. [PubMed: 12583753] (e) Ball M, Baron A, Bradshaw B, Omori H, McCormick S, Thomas EJ. *Tetrahedron Lett* 2004;45:8737–8740. (f) Keck GE, Truong AP. *Org. Lett* 2005;7:2149–2152. [PubMed: 15901156] (g) Keck GE, Yu T, McLaws MD. *J. Org. Chem* 2005;70:2543–2550. [PubMed: 15787541]
11. Keck GE, Covell JA, Schiff T, Yu T. *Org. Lett* 2002;4:1189–1192. [PubMed: 11922815]
12. Keck GE, Truong AP. *Org. Lett* 2005;7:2153–2156. [PubMed: 15901157]
13. (a) Keck GE, Castellino S, Wiley MR. *J. Org. Chem* 1986;51:5478–5480. (b) Evans DA, Duffy JL, Dart MJ. *Tetrahedron Lett* 1994;35:8537–8540. (c) Reetz MT. *Acc. Chem. Res* 1993;26:462–468. and references cited therein
14. The authors recognize this aldehyde to be achiral in its current depiction and thus incapable of participating in a diastereoselective reaction. The intention is simply to convey the strategy for utilizing the C₅ center to relay stereochemical information in two independent operations
15. Keck GE, Tarbet KH, Geraci LS. *J. Am. Chem. Soc* 1993;115:8467–8468.
16. Keck GE, Welch DS, Vivian PK. *Org. Lett* 2006;8:3667–3670. [PubMed: 16898787]
17. For a similar synthetic sequence involving introduction of a 1,1'-dimethyl unsaturated olefin, see Hirai K, Ooi H, Esumi T, Iwabuchi Y, Hatakeyama S. *Org. Lett* 2003;5:857–859. [PubMed: 12633090]
18. (a) Doering, W. v. E.; Haines, MR. *J. Am. Chem. Soc* 1954;76:482–486. (b) Fish PV, Johnson WS. *J. Org. Chem* 1994;59:2324–2335.
19. Weigand S, Brückner R. *Synthesis* 1996:475–482.
20. Evans DA, Allison BA, Yang MG, Masse CE. *J. Am. Chem. Soc* 2001;123:10840–10852. [PubMed: 11686685]
21. Tanaka K, Ohta Y, Fuji K, Taga T. *Tetrahedron Lett* 1993;34:4071–4074.

Scheme 1.
Retrosynthetic approach to bryostatin 1.

Scheme 2.

Reagents and conditions: (a) (S)-(-)-1,1'-bi-2-naphthol, $\text{Ti}(\text{O}i\text{-Pr})_4$, 4 Å MS, CH_2Cl_2 , -20°C , 5 days, 90%, 93% ee; (b) PMBOC(NH)CCl₃, CSA, CH_2Cl_2 , rt, 12 h, 76%; (c) TBAF, THF, rt, 12 h, 95%; (d) $\text{SO}_3\cdot\text{py}$, $\text{Et}(i\text{-Pr})_2\text{NH}$, DMSO, CH_2Cl_2 , -5°C , 30 min, 97%; (e) TBDPSCl, imidazole, DMF, rt, 24 h, 92%; (f) OsO_4 , NMO, $t\text{-BuOH/THF/H}_2\text{O}$, rt, 14 h; (g) $\text{Pb}(\text{OAc})_4$, PhH, rt, 1 h, 99% (two steps).

Scheme 3.

Reagents and conditions: (a) LDA, THF, $-78\text{ }^{\circ}\text{C}$, 30 min; 2-iodo-1-(*t*-butyldimethylsiloxy)ethane, $-78\text{ }^{\circ}\text{C}$ to rt, 15 h, 79%; (b) *t*-BuOK, THF, $0\text{ }^{\circ}\text{C}$, 2 h, 93%; (c) DIBAL, CH_2Cl_2 , $0\text{ }^{\circ}\text{C}$, 2 h, 94%; (d) *n*-BuLi, THF, $-78\text{ }^{\circ}\text{C}$, 45 min; MsCl, $-78\text{ }^{\circ}\text{C}$, 1.25 h; Bu_3SnLi , $-78\text{ }^{\circ}\text{C}$ to rt, 20 h, 72%.

Scheme 4.

$\text{C}_7\text{-C}_8$ bond construction and installation of the *gem*-dimethyl moiety.

Scheme 5.

Reagents and conditions: (a) Ac_2O , DMAP, Et_3N , CH_2Cl_2 , rt, 24 h, 94%; (b) DDQ, 2:1 $\text{CH}_2\text{Cl}_2/\text{pH 7.0 buffer}$, rt, 2 h, 94%; (c) O_3 , CH_2CH_2 , -78°C , 5 min; DMS, rt, 12 h, 91%; (d) CSA, MeOH, rt, 1.25 h, 99%; (e) $\text{SO}_3\cdot\text{py}$, $\text{Et}(i\text{-Pr})_2\text{NH}$, DMSO, CH_2Cl_2 , -5°C , 1 h, 88%.

Scheme 6.
Formation of the B-ring by pyran annulation.